|[May 02, 2014]
Two Clinical Studies Featuring C2 Therapeutics' Cryoballoon Focal Ablation System to be Presented at DDW 2014
REDWOOD CITY, Calif. --(Business Wire)--
C2 Therapeutics, a privately held company founded to improve treatment
of precursors to esophageal cancer, today announced that data from two
clinical studies evaluating the therapeutic impact of its Coldplay
Cryoballoon Focal Ablation System will be presented at Digestive Disease
Week® (DDW®), on May 6th in Chicago, IL.
"The clinical studies at DDW evaluating the Coldplay Cryoballoon Focal
Ablation System highlight our commitment to advancing the field of
treatment for precursors to esophageal cancer," said Peter Garcia-Meza,
President and CEO of C2 Therapeutics. "Treatment options to precursors
such as Barrett's Esophagus need to be improved, and we believe the
results of these trials will confirm the potential benefits of our
technology for physicians around the world to help improve patient
Schedule of Poster Presentations:
Monday, May 6 -- All posters are available from 8:00 a.m. - 5:00 p.m.,
Room -- ASGE Posters - Esophagus
Poster 1- TU1356:
Clinical evaluation of a new
Cryoballoon Focal Ablation System for the elimination of Barrett's
esophagus presented by Bas Weusten. The aim of the study
was to assess the feasibility, safety, and dose-response of the newl
Coldplay Cryoballoon Focal Ablation in patients with flat BE with or
without dysplasia. Results on 33 patients are presented.
- D. Schölvinck, J. Bergman, C. Kestens, P. Siersema, F. Vleggaar, M.
Canto, H. Cosby, J. Abrams,C. Lightdale, E. Tejeda-Ramirez, S.
DeMeester, C. Greene, B. Jobe, T. Hoppo, J. Peters, B. Weusten
Poster 2 - TU1385
Deep tissue ablation with little or
no late fibrosis: animal and human data on esophageal cryoablation using
the new Cryoballoon Focal Ablation System (TU1385) presented by Dirk
Schölvinck. The aim of the study was to evaluate depth of
tissue injury after Cryoballoon Focal Therapy. Results
presented on 19 ablations in 5 animals and 4 ablations in 3 humans.
- D. Schölvinck, B. Weusten, G. Triadafilopoulos, T. Valli, S. Friedland
About Barrett's Esophagus
Barrett's Esophagus is a pre-cancerous condition of the esophagus
commonly associated with gastric reflux disease (GERD) which affects as
many as 60 million Americans. 3.5 MM people in the US have Barrett's and
if left untreated, it can develop into adenocarcinoma, which is one of
the most rapidly increasing and deadliest cancers in the United States.
The risk of developing cancer with BE is 30 to 125 times higher than
those without this condition. The 5-year survival rate is near 15%.
About C2 Therapeutics
C2 Therapeutics was founded in 2007 to address the limitations of
current Barrett's Esophagus treatment options. Headquartered in Redwood
City, California, C2 is a privately held company whose C2's Coldplay
Cryoballoon Focal Ablation System sets a new standard for simplicity in
ablation of Barrett's Esophagus. The device is a through-the-scope,
highly compliant balloon catheter that is simultaneously inflated and
cooled by an inert refrigerant delivered from a small disposable
handheld unit. Operation is intuitive, fast, and cost-effective. The C2
Coldplay Cryoballoon Focal Ablation System eliminates the need for
precise sizing, multiple deployment steps, and controller units.
For more information on C2 Therapeutics and its products, please visit http://www.c2therapeutics.com/.
[ Back To TMCnet.com's Homepage ]